Healthcare Equipment and Supplies
Company Overview of ReVision Optics, Inc.
ReVision Optics, Inc. develops and commercializes optical solutions for the treatment of presbyopia in the United States, Europe, Canada, Japan, and Australia. It offers Raindrop Near Vision Corneal Inlay, a refractive surgery solution, which is designed to improve the near vision that has been lost by the eye’s natural aging process, called presbyopia. The company was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in October 2005. ReVision Optics, Inc. was founded in 1996 and is based in Lake Forest, California.
25651 Atlantic Ocean Drive
Lake Forest, CA 92630-8835
Founded in 1996
Key Executives for ReVision Optics, Inc.
Vice President of Operations
Chief Compliance Officer and Vice President of Regulatory Affairs & Quality Assurance
Compensation as of Fiscal Year 2014.
ReVision Optics, Inc. Key Developments
NovaMedika Enters into Collaboration Agreement with ReVision Optics
Aug 1 13
NovaMedika has entered an agreement with ReVision Optics for the latter's Raindrop Near Vision Corneal Inlay technology. Under the terms of the agreement, NovaMedika gains exclusive rights to commercialize products developed with that technology in Russia and the Commonwealth of Independent States. The technology is in late Phase III trials and is being developed for the correction of vision in patients with presbyopia and refraction anomalies by inserting a hydrogel insert under the cornea of the eye. The agreement reportedly involves both therapeutic 'substances' and medical equipment, and is important for NovaMedika as it tries to emerge as a player in originator innovative technologies in a market where most domestic companies are focused on generics.
ReVision Optics, Inc. Presents at Investment-In-Innovation (IN3) Medical Device 360 Degrees Dublin, Apr-16-2013 11:40 AM
Apr 8 13
ReVision Optics, Inc. Presents at Investment-In-Innovation (IN3) Medical Device 360 Degrees Dublin, Apr-16-2013 11:40 AM. Venue: The Shelbourne Dublin, Dublin, Ireland.
ReVision Optics, Inc. Receives FDA Approval to Complete Enrollment in its Phase III Clinical Trial with the Raindrop Near Vision Inlay for Improving Near Vision in Patients with Presbyopia
Feb 25 13
ReVision Optics, Inc. announced that it has received conditional approval from the U.S. Food and Drug Administration to continue and complete enrollment in its Phase III clinical trial with its Raindrop(TM) Near Vision Inlay (formerly the PresbyLens(R)). The prospective, multicenter Phase III clinical trial is evaluating the safety and effectiveness of the patented, proprietary Raindrop Near Vision Inlay in improving near vision in subjects with presbyopia under an Investigational Device Exemption. In early January 2013, RVO submitted six-month follow-up data to the FDA from 75 of 100 subjects enrolled in the first portion of the Phase III clinical trial. Highlights of the submitted data include: 100% of subjects had an uncorrected near visual acuity of 20/25 (J1) or better in the treated eye. All subjects (100%) achieved 20/25 (J1) or better when tested bilaterally; 97% of subjects had an uncorrected intermediate visual acuity of 20/32 or better in the treated eye. 99% of subjects achieved 20/32 or better when tested bilaterally; 96% of subjects had an uncorrected distance visual acuity of 20/40 or better in the treated eye. All subjects (100%) achieved 20/20 or better when tested bilaterally; 91% of subjects gained 4 lines or more of uncorrected near visual acuity in the treated eye as measured on a standard eye chart; None of the subjects had a loss of >=2 lines best corrected distance vision compared to their pre-operative measurements; 94% of subjects were satisfied with the correction they received following the Raindrop inlay implant. In addition to ReVision Optics' success in its efforts to complete Phase III of its U.S. IDE, the company recently initiated a controlled commercial launch of the Raindrop Near Vision Inlay in both Europe and Asia.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|